Trial Profile

Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nintedanib (Primary) ; Carboplatin; Paclitaxel
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Registrational; Therapeutic Use
Acronyms LUME-Ovar-1; OVAR12
Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG; Boehringer Ingelheim Pharmaceuticals

15 Jan 2020 Results published in the International Journal of Cancer
13 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
06 Jun 2017 Results (n=1355) of exploratory analysis assessing the prognostic value of tumor residuals, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com